Prescription drug · ANDA
Methenamine Hippurate NDC 60687-694
Methenamine hippurate 1000 mg/1 · Tablet · Oral · American Health Packaging
NDC codes
FDA NDC Directory| Package NDC | 11-digit (billing) | Package | Copy |
|---|---|---|---|
| 60687-694-21 | 60687069421 | 30 BLISTER PACK in 1 CARTON (60687-694-21) / 1 TABLET in 1 BLISTER PACK (60687-694-11)Marketed from Aug 12, 2022 |
How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules
Product information
- Brand name (proprietary)
- Methenamine Hippurate
- Generic name (nonproprietary)
- methenamine hippurate
- Active ingredients
- Methenamine hippurate — 1000 mg/1
- Dosage form
- Tablet
- Route
- Oral
- Labeler
- American Health Packaging
- Product type
- Prescription drug
- Marketing category
- ANDA — Abbreviated New Drug Application (generic)Application ANDA 212172
- Marketing start
- Listing expires
- Identifiers
- Product ID 60687-694_22ddc289-92bd-d459-e063-6394a90af811SPL ID 22ddc289-92bd-d459-e063-6394a90af811SPL set ID fcb9b18a-6e6d-42c7-bc85-c61cb1c4a3beRxCUI 992150UNII M329791L57
Billing references
What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.
- HCPCS codeNo match
No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.
- NDC on a medical claim
N460687069421followed by a unit qualifier and the quantityPackage 60687-0694-21. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier
Product label
Current FDA label (SPL), effective .
Indications (excerpt from the label)
INDICATIONS Methenamine hippurate tablets USP are indicated for prophylactic or suppressive treatment of frequently recurring urinary tract infections when long-term therapy is considered necessary. This drug should only be used after eradication of the infection by other appropriate antimicrobial agents. To reduce the development of drug-resistant bacteria and maintain the effectiveness of methenamine hippurate and other antibacterial drugs, methenamine hippurate should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or mod…
Excerpt only. Read the full label for complete information.